title: Melatonin effect on bone metabolism in rats treated with methylprednisolone.
abstract: The present study was undertaken to examine the effect of melatonin (25 microg/mL of drinking water, about 500 microg/day) on a 10-wk long treatment of male rats with methylprednisolone (5 mg/kg s.c., 5 days/wk). Bone densitometry and mechanical properties, calcemia, phosphatemia and serum bone alkaline phosphatase activity and C-telopeptide fragments of collagen type I (CTX) were measured. Both melatonin and methylprednisolone decreased significantly body weight (BW) and the combination of both treatments resulted in the lowest BW values found. Consequently, all results were analyzed with BW as a covariate. Densitometrically, methylprednisolone augmented bone mineral content (BMC), bone area (BA) and bone mineral density (BMD) in the entire skeleton, BMC in cortical bone, and BMC and BMD in trabecular bone. Melatonin increased BMC and BA in whole skeleton and BMC and BMD in trabecular bone. For BMC and BA of whole skeleton, BMC of cortical bone, and BMC and BMD of trabecular bone, the combination of glucocorticoids and melatonin resulted in the highest values observed. Femoral weight of rats receiving methylprednisolone or melatonin increased significantly and both treatments summated to achieve the greatest effect. In femoral biomechanical testing, methylprednisolone augmented ultimate load and work to failure significantly. Rats receiving the combined treatment of methylprednisolone and melatonin showed the highest values of work to failure. The circulating levels of CTX, an index of bone resorption, decreased after methylprednisolone or melatonin, both treatments summating to achieve the lowest CTX values found. Serum calcium increased after methylprednisolone and serum phosphorus decreased after treatment with methylprednisolone or melatonin while serum bone alkaline phosphatase levels remained unchanged. The results are compatible with the view that low doses of methylprednisolone or melatonin decrease bone resorption and have a bone-protecting effect.
authors.affiliation: Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
authors.forename: Marta G
authors.initials: MG
authors.lastname: Ladizesky
authors.forename: Verónica
authors.initials: V
authors.lastname: Boggio
authors.forename: Rodolfo A
authors.initials: RA
authors.lastname: Cutrera
authors.forename: Nélida
authors.initials: N
authors.lastname: Mondelo
authors.forename: Silvina
authors.initials: S
authors.lastname: Mastaglia
authors.forename: Julia
authors.initials: J
authors.lastname: Somoza
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Cardinali
mesh_terms: D000818:Animals; D015519:Bone Density; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D008550:Melatonin / Q000494:pharmacology*; D008775:Methylprednisolone / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D013054:Spectrophotometry, Atomic
chemical_list: D008550:Melatonin; D008775:Methylprednisolone